Day Zero Diagnostics and Oxford Nanopore today announced a collaboration to develop a solution for diagnosing bloodstream infections. Boston-based Day Zero Diagnostics develops diagnostics utilizing whole-genome sequencing and AI to combat antibiotic-resistant infections. Oxford Nanopore offers a new generation of nanopore-based molecular sensing technology. They seek to enable early detection to combat bloodstream infections as […]
Day Zero Diagnostics
Boston Scientific executive is Day Zero Diagnostics’ new board chair
Day Zero Diagnostics — which seeks to harness whole-genome sequencing and AI in the fight against antibiotic-resistant infections — has a Boston Scientific executive as its new board chair. Jeff Mirviss is presently EVP and president of the Peripheral Interventions Division at Boston Scientific. He was already an independent director on Boston-based Day Zero Diagnostics’ […]
Day Zero Diagnostics completes $16M funding round
Day Zero Diagnostics — which seeks to harness whole-genome sequencing and AI in the fight against antibiotic-resistant infections — announced today that it has successfully wrapped up a $16M financing round. The latest round raises the Boston-based company’s venture capital funding total to $49M, coupled with over $18M in non-dilutive funding. “This funding is a […]
22 MedTech Innovator all-stars will pitch at DeviceTalks Boston
Nearly two dozen MedTech Innovator portfolio startups will pitch their technology to medtech industry innovators, executives and engineers at DeviceTalks Boston on May 10-11. The MedTech Innovator accelerator program picked the 22 all-stars from hundreds of applicants. The all-stars who will be featured over the two-day event at the Boston Convention and Exhibition Center are: […]
Day Zero Diagnostics raises $8.2M from CARB-X
Day Zero Diagnostics announced that it received an $8.2 million award in optional stage funding from CARB-X. The infectious disease diagnostic developer received an initial $6.2 million CARB-X award in May 2020. CARB-X, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, aims to accelerate early antibacterial R&D. This would address the rising global threat of drug-resistant […]
Day Zero Diagnostics raises $21M
Infectious disease diagnostic company Day Zero Diagnostics announced today that it completed a venture equity financing worth $21 million. Sands Capital led the financing round, while significant participation came from new investors, including BD, Panacea Venture and Hongkou Capital. There was also participation from existing investors, including Triventures and Golden Seeds. To date, Zero Day […]
Day Zero Diagnostics wins $6.2m from accelerator
Day Zero Diagnostics announced that it received an award of up to $6.2 million in non-dilutive funding from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). The funding from the non-profit partnership dedicated to accelerating early antibacterial R&D is intended to support Day Zero’s diagnostic system designed to help physicians diagnose and treat life-threatening bacterial infections. […]
